Logotype for MustGrow Biologics Corp

MustGrow Biologics (MGRO) Status update summary

Event summary combining transcript, slides, and related documents.

Logotype for MustGrow Biologics Corp

Status update summary

28 Oct, 2026

Market opportunity and positioning

  • Biologicals market expected to reach ~$20B, with mid-teens CAGR over the next ~5–8 years, within a $380B global market for chemicals, fertilizers and biologicals.

  • Consumer interest in food production and farmer demand for additional solutions are supporting biologicals’ growth across a broad range of technologies.

  • TerraMG and TerraSante are positioned as science-backed products; adoption depends on demonstrating field performance and value to growers.

  • Biologicals are framed as complementary tools in integrated pest management, alongside chemistry, seeds and fertilizers, rather than standalone solutions.

EMEA partnership and market fit

  • Europe is a priority for biologicals amid stricter regulation, fewer chemical crop-protection options and restrictions on synthetic fertilizers; high-value fruit and vegetable crops are a focus.

  • Regional consumer demand and regulatory pathways distinguish Europe from North America; local expertise and resources make Bayer a key route into EMEA markets.

  • Bayer contributes scientific testing, field validation and region-specific regulatory expertise, supporting international development and commercialization.

  • Bayer sees biologicals as part of farmers’ broader toolkit for crop protection, performance and more responsible food systems; partnerships can help scale solutions to more growers.

TerraMG evaluation and progress

  • A technical milestone confirmed TerraMG formulation compatibility with European farming practices and standard application equipment, with effective handling and application.

  • Field studies under real conditions confirmed meaningful disease control, with assessment focused on soil-borne diseases.

  • Bayer’s nearly two-year pre-partnership evaluation included lab and greenhouse tests, field trials, EU regulatory feasibility and intellectual-property assessment; the commercial agreement followed in Dec 2023.

  • Bayer highlighted TerraMG’s fit with demand for effective biological alternatives to address nematode-related crop yield and quality losses, particularly in fruits and vegetables.

Partial view of Summaries dataset, powered by Quartr API
AI can get things wrong. Verify important information.
All investor relations material. One API.
Learn more

Latest events from MustGrow Biologics